Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 30 Jun, 11:00 pm
Arete Research downgraded The Trade Desk (NASDAQ: TTD) to a Sell rating with a price target of $11.60 . The Trade Desk stock recently hit a new 52-week low of $16.98 , reflecting a 50% year-to-date decline. The company reported a significant slowdown in revenue growth to 12% year
Citigroup maintains a "Buy" rating for Zymeworks , raising its price target to $37 from $35 . Zymeworks is set to acquire Theravance Biopharma in an all-cash transaction valued at approximately $929 million , adding the COPD treatment YUPELRI® to its portfolio. The acquisition is
Robert W. Baird downgraded Alpine Income Property Trust to a "Neutral" rating with a $21.00 price target, despite its shares trading slightly higher at $21.26 . The REIT demonstrates robust operational performance, including an 11% compound annual growth rate in AFFO per share, a
Fortinet (NASDAQ: FTNT) received a "Reduce" rating from HSBC (NYSE: HSBC) with a price target of $102.00 , suggesting a potential 34.37% downside. Despite the downgrade, the cybersecurity stock has shown positive market activity, with a 2.69% gain in the latest session and 9.7% o
Boundless Bio, Inc. (NASDAQ: BOLD) is set to merge with Serapha Bio, Inc., forming a new entity focused on advancing a program for Alpha-1 Antitrypsin Deficiency (AATD) . A significant insider, TANG KEVIN, recently increased their stake in Boundless Bio, Inc., acquiring 63,985 sh
Concentrix reported an earnings per share (EPS) of $2.63 , slightly missing the analyst consensus estimate of $2.64 . Despite a narrow miss on estimates, quarterly revenue grew by 1.9% year-over-year, reaching $2.46 billion . The company maintains sound financial health with a De
Constellation Brands (NYSE:STZ) is navigating challenges from declining alcohol demand and shifting consumer preferences. Analysts forecast a 1.9% increase in earnings per share (EPS) to $3.28 , despite an anticipated 3.9% decrease in revenue to $2.42 billion . Options markets su
Affirm Holdings (NASDAQ:AFRM) Stock Analysis: Analyst Ratings and Market Performance Piper Sandler initiated coverage on Affirm Holdings (NASDAQ:AFRM) with an Overweight rating and a $103.00 price target , indicating a positive investment outlook. The company's shares have demons
Despite an analyst downgrade from HSBC, Fortinet (NASDAQ: FTNT) stock demonstrated strong market resilience, closing at $155.42 and reaching a new 52-week high of $159.04 . The company is strategically expanding its product portfolio, including new FortiGate G Series models with
AeroVironment (NASDAQ: AVAV) exceeded analyst expectations with strong quarterly earnings per share (EPS) of $1.84 and robust revenue of $641.62 million . The company experienced substantial growth, with revenue more than doubling year-over-year and its stock price increasing by
FactSet Research Systems Inc. (NYSE:FDS) is projected to report strong third-quarter earnings with an estimated EPS of $4.44 and revenue of $617.91 million , reflecting year-over-year growth. The company's growth is bolstered by robust regional performance in the Americas and Asi
Analyst firm Piper Sandler reduced its price target for PayPal, maintaining a Neutral rating due to cautious sentiment. PayPal is facing significant growth challenges, with slowing revenue growth and modest daily active user increases, contributing to a substantial stock decline
Mixed Insider Activity: While the CFO sold shares, a director made significant open-market purchases, suggesting differing internal views or strategic moves within the company. Post-Earnings Buying Signals Confidence: A director's substantial share purchases followed a Q2 earning
Clinical Trial Impact: Biotech stock valuations, exemplified by Evommune, Inc. (NASDAQ: EVMN) , are highly susceptible to clinical trial results. Company-Specific News: Significant stock declines can be triggered by specific company announcements or developments, as seen with Fre
Acquisitions and successful financing are major catalysts for significant stock price increases. Leadership appointments can positively influence investor confidence and company valuation. Leveraged ETFs can amplify returns during broader market rallies, reflecting wider market t
Strong Analyst Sentiment : Merck & Co., Inc. (NYSE: MRK) holds an average brokerage recommendation of 1.73 , indicating a "Strong Buy" to "Buy" rating for the pharmaceutical stock. Increased Price Target : Scotiabank raised its price target for Merck to $155 , signaling increased
The consensus price target for Nike has significantly decreased over the past year, reflecting adjusted expectations due to recent performance and market conditions. Analysts project a notable decline in Nike's Q4 revenue, operating income, and EPS, indicating potential headwinds
Wedbush analyst Laura Chico has increased her price target for Viridian Therapeutics to $43 , signaling strong confidence in the biopharmaceutical company's future. The U.S. Food and Drug Administration (FDA) has approved Viridian Therapeutics' new drug, Lumvoa, for Thyroid Eye D
Headlines provided by Investing.com